This is a StreetInsider.com Premium Only Page

Ultimovacs (ULTI) – Globe Newswire

Oct 18, 2022 02:00 AM Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility

Jun 30, 2022 02:00 AM Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Mar 21, 2022 03:00 AM Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma

Feb 17, 2022 02:00 AM Ultimovacs ASA: Fourth quarter 2021 result presentation

Feb 3, 2022 02:00 AM Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

Dec 15, 2021 02:00 AM First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

Dec 2, 2021 01:00 PM Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

Nov 11, 2021 02:00 AM Ultimovacs ASA: Third quarter 2021 result presentation

Nov 9, 2021 08:00 AM Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma

Oct 26, 2021 06:23 PM Ultimovacs ASA - Private placement of new shares successfully placed

Oct 26, 2021 10:47 AM Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)

Oct 21, 2021 02:05 AM Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

Oct 13, 2021 02:33 AM Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

Oct 1, 2021 06:35 AM Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Aug 20, 2021 02:05 AM Ultimovacs ASA: Second Quarter 2021 Result Presentation

Aug 12, 2021 01:50 AM Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma

Aug 11, 2021 11:05 AM Ultimovacs ASA: Invitation to Second Quarter 2021 Results Webcast Presentation

Aug 5, 2021 02:05 AM Ultimovacs Announces First Patient Enrolled in Phase II FOCUS Trial of UV1 in Head-and-Neck Cancer

Jul 5, 2021 03:40 PM Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Jun 4, 2021 09:05 AM Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Jun 1, 2021 08:00 AM Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

May 19, 2021 04:56 PM Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data